Europe Clinical Trials Market Overview
The Europe clinical trials market is expected to register a growth rate of about 4.4% over the forecast period, 2018 to 2023. The clinical trials under clinical research in healthcare are performed following a regulated protocol. Europe possesses a large number of pharmaceutical and biotech companies with rich universities background across several countries. In addition, the countries in the Europe has reported growth in geriatric population which primarily drives growth of clinical trials in this region.
High R&D Expenditure on Clinical Trials by Pharmaceutical Companies Boosts the Europe Clinical Trials Market
As per the Organization for Economic Co-operation and Development (OECD), the expenditure by pharmaceutical industry on R&D is highest in the US, followed by Japan and Europe. As per the PhRMA (Pharmaceutical Research and Manufacturers of America), Annual Membership Survey, 2016, the largest number drugs are in phase II category followed by phase I and III, particularly in developed markets. In addition, the pharmaceutical companies spend about 30% of the R&D in phase III followed by II, I and preclinical. With that, the companies have major focus on oncology, cardiovascular, diabetes and respiratory diseases. According to European Commission Statistics, 2014, 5 out of 11 the leading R&D firms were pharmaceutical companies which have rich pipeline portfolios for multiple indications. With high focus on vaccines and biologics for large number of chronic diseases management, the increasing R&D expenditure is one of the primary drivers for the Europe clinical trials market.
Other factors, driving this market are rising prevalence of chronic diseases with aging population, increasing focus towards rare diseases and orphan drugs development.
Data Privacy Concerns has hit as a major Barrier for Europe Clinical Trials Market
Big data is becoming an increasingly important part of clinical research with the rising use of electronic records, advancements of clinical trial technologies for collection and use of data. However, the data security and privacy concerns has intensified in Europe in past few years. With increasing list of important compliance requirements, the life science officers faces a lot of challenges from General Data Protection Regulation (“GDPR”). In clinical trials, several times, the patients choose to withdraw their consent to prevent any additional data collection because of personal security reasons which often slows down the process of clinical trials. The changes as per the GDPR for Europe data protection framework has been significant and adoption is expected to be gradual as the companies would need better solutions over the forecast period, to support the GDPR requirements for Europe clinical trials operations. Hence, data privacy is a major restraint over the forecast period.
Other important barrier in this market is stringent regulations for patient enrollment in clinical trials.
Germany is Expected to lead with largest share in the Europe Clinical Trials Market
Germany is among the most competitive location for clinical research in Europe with high quality of infrastructure, healthcare expenditure, and data management. Germany is highly engaged in the clinical trial market, with more than 75% of the clinical trials being industry funded. Clinical trials conducted in Germany facilitate product development for European market and have high international recognition. The contract research organizations such as KOEHLER eClinical has played a significant role in providing clinical research services to the biopharmaceutical industry and life science organizations. Over the forecast period, growth is expected to be gradual with several upcoming biopharmaceutical companies targeting Germany as the major hot spot for the clinical trials in Europe.
Key Developments in the Europe Clinical Trials Market
- Jul 2018: BrainStorm Cell Therapeutics Inc announced that the European Patent Office ("EPO") has granted a European-wide patent, which protects NurOwn in Europe until 2029.
- Jul 2018: Omeros Corporation received a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell transplantation by European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP).
The major players include - ICON, Clinipace, IQVIA, Pfizer Inc, and F. Hoffmann-La Roche AG, among others.
An increasing number of biopharmaceutical companies try to collaborate with large contract research organizations (CROs) across major countries in Europe. Over the forecast period, this trend is expected to increase further, as more companies moving forward with preclinical product candidates into clinical trials phase.
Europe Clinical Trails Market Report Summary
Europe Clinical Trials Market
(2015 - 2023)
UK, Germany France, Italy Spain and Rest of Europe
Germany has largest share in this market in Europe
Jul 2018: BrainStorm Cell Therapeutics Inc announced that the European Patent Office
ICON, Clinipace, Eli Lilly and Company, F. Hoffmann-La Roche AG, IQVIA, Novo Nordisk A/S, Paraxel International Corporation, Pfizer Inc, Pharmaceutical Product Development, LLC, and
Pharmaron, among others.
Europe Clinical Trials Market offers latest trends, growth prospects, industry competitiveness, major players, regional share of market and forecast to 2023.
Reasons to Purchase the Europe Clinical Trials Market Report
- Current and future of Europe clinical trials market outlook in the developed and emerging markets
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Europe Clinical Trials Market Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 High R&D Spending on Clinical Trials by the Pharmaceutical Industry in Developed Markets
6.1.2 Rising Prevalence of Chronic Diseases with Aging Population
6.1.3 Increasing Focus on Rare Diseases and Orphan Drugs in Pipeline
6.2 Market Restraints
6.2.1 Data Privacy Concerns
6.2.2 Stringent Regulations for Patient Enrollment In Clinical Trials
6.4 Key Challenges
7. Market Segmentation
7.1 By Phase
7.1.1 Phase I
7.1.2 Phase II
7.1.3 Phase III
7.1.4 Phase IV
7.2 By Design
7.2.1 Treatment Studies
126.96.36.199 Randomized Control Trial
188.8.131.52 Adaptive Clinical Trial
184.108.40.206 Non-Randomized Control Trial
7.2.2 Observational Studies
220.127.116.11 Cohort Study
18.104.22.168 Case Control Study
22.214.171.124 Cross Sectional Study
126.96.36.199 Ecolgical Study
7.3 By Geography
7.3.6 Rest of Europe
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.3 Eli Lilly and Company
9.4 F. Hoffmann-La Roche AG
9.6 Novo Nordisk A/S
9.7 Paraxel International Corporation
9.8 Pfizer Inc
9.9 Pharmaceutical Product Development, LLC
**List Not Exhaustive
10. Future Market Outlook